Loading company…
Tokyo drug delivery company combining immunotherapy with nanoparticle technology for cancer and autoimmune disease treatments.
Founded in 2017 and based in Tokyo, Japan, United Immunity, Co., Ltd. develops drug delivery systems that combine immunotherapy with nanoparticle technology, and was founded by Naozumi Harada. Its Pullulan-based nanoparticles deliver therapies to myeloid cells for cancer and autoimmune disorders, earning licensing and milestone revenue from pharmaceutical partners. In September 2026 the company raised JPY 1.8 billion in venture funding as part of a JPY 2.2 billion equity and venture debt round, and it received JPY 2.8 billion in grant funding from the Japan Agency for Medical Research and Development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in